Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and meet that unmet need. In the longer term, we see a great opportunity to use our IP from the ALS arena to move on to target the wider range of neurodegenerative diseases.
The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.
The NIHR:
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early-stage start-ups, leading academic groups, and not-for-profit companies.
ImmunoINSIGHTS is Oncimmune’s service to the life science industry, built off the company’s proprietary autoantibody profiling technology. Underpinned by Oncimmune’s proprietary high throughput immunogenic protein library, one of the largest in the world, covering more than 95% of known human antigens, the technology can be utilised for profiling autoantibodies in patients receiving or about to receive treatment. This unique combination of Oncimmune’s core technology and understanding of the immune system enables life-science organisations to optimise drug development, leading to more effective, targeted, as well as safer treatments for patients.
Onyx Scientific is a small molecule CDMO specialising in process R&D, non-GMP scale up and GMP manufacture for clinical trials and commercial. Good chemistry is at the core of everything we do. From our facilities in the UK and US, our teams of chemists will guide your small molecule API through development and manufacturing from the moment a lead molecule is identified, taking it into Phase I studies and right through to commercial manufacture.
Paspigioni is a full-service CRO that offers cost-effective, high-quality clinical trials from Phases I to IV. They also provide medical device studies, often with a rapid start-up.
They operate across 19 emerging markets in Central and Eastern Europe, the Balkans, and Asia, ensuring a competitive edge for their partners. Using a CRO-in-a-box approach, Paspigioni launches and manages trials in different countries and supports biotech and pharma companies with efficient solutions. They guide their partners through new clinical landscapes, offering operational excellence and reliable results. They enable access to untapped patient populations, and provide local market expertise and a clear regulatory path.
Pencil Biosciences is developing a truly innovative gene editing technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. The technology is small, modular in design, and non-CRISPR in composition.
Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments.
They work with partners developing cancer drugs to help them save time and money and achieve better outcomes during pre-clinical and clinical development. They are also developing tools to support cancer treatment in real world settings
Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.
Poolbeg Pharma plc (AIM: POLB) is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Contact Precision for Medicine, Oncology and Rare Disease via their website
